| Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19 PL Turecek, RC Peck, S Rangarajan, C Reilly-Stitt, MA Laffan, R Kazmi, ... Thrombosis research 201, 100-112, 2021 | 50 | 2021 |
| Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease? MB Abid, R Peck, MA Abid, W Al‐Sakkaf, Y Zhang, GS Dunnill, K Staines, ... Hematological Oncology 36 (1), 320-323, 2018 | 15 | 2018 |
| Diagnostic uncertainty presented barriers to the timely management of acute thrombotic thrombocytopenic purpura in the United Kingdom between 2014 and 2019 TP Bull, R McCulloch, PLR Nicolson, AJ Doyle, RJ Shaw, A Langridge, ... Journal of Thrombosis and Haemostasis 20 (6), 1428-1436, 2022 | 13 | 2022 |
| Experience of Covid 19 vaccination in patients with bleeding disorders RC Peck, A Clark, S Shapiro Haemophilia 28 (1), e9, 2021 | 5 | 2021 |
| Scoping review of factors associated with stem cell mobilization and collection in allogeneic stem cell donors RC Peck, A Knapp-Wilson, K Burley, C Dorée, J Griffin, AD Mumford, ... Transplantation and Cellular Therapy, 2024 | 2 | 2024 |
| Pseudohomozygous dysfibrinogenemia RC Peck, L Fitzgibbon, C Reilly‐Stitt, C Doherty, E Phillips, AD Mumford Research and Practice in Thrombosis and Haemostasis 5 (6), e12568, 2021 | 2 | 2021 |
| Comprehensive Description of Monoallelic GP1BA Variants Associated with Thrombocytopenia RC Peck, S Westbury, L Fitzgibbon, NV Morgan, J Rivera, WH Kahr, ... Blood 136, 34-35, 2020 | 2 | 2020 |
| S., Staines, K., Sequeiros, IM, & Lowry, L.(2018). Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease? Hematological Oncology, 36 (1 … MB Abid, R Peck, MA Abid, W Al-Sakkaf, Y Zhang, G Dunnill | | |
| S.,... Lowry, L.(2018). Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease? Hematological Oncology, 36 (1), 320-323. https://doi. org/10 … MB Abid, R Peck, MA Abid, W Al-Sakkaf, Y Zhang, G Dunnill | | |
